Abstract
The mitogen-activated extracellular signal-regulated kinase/extracellular signal-regulated kinase (MEK/ERK) and phosphatidylinositol 3-kinase (PI3K)/AKT pathways are often concurrently activated by separate genetic alterations in colorectal cancer (CRC), which is associated with CRC progression and poor survival. However, how activating both pathways is required for CRC metastatic progression remains unclear. Our recent study showed that both ERK and AKT signaling are required to activate eukaryotic translation initiation factor 4E (eIF4E)-initiated cap-dependent translation via convergent regulation of the translational repressor 4E-binding protein 1 (4E-BP1) for maintaining CRC transformation. Here, we identified that the activation of cap-dependent translation by cooperative ERK and AKT signaling is critical for promotion of CRC motility and metastasis. In CRC cells with coexistent mutational activation of ERK and AKT pathways, inhibition of either MEK or AKT alone showed limited activity in inhibiting cell migration and invasion, but combined inhibition resulted in profound effects. Genetic blockade of the translation initiation complex by eIF4E knockdown or expression of a dominant active 4E-BP1 mutant effectively inhibited migration, invasion and metastasis of CRC cells, whereas overexpression of eIF4E or knockdown of 4E-BP1 had the opposite effect and markedly reduced their dependence on ERK and AKT signaling for cell motility. Mechanistically, we found that these effects were largely dependent on the increase in mammalian target of rapamycin complex 1 (mTORC1)-mediated survivin translation by ERK and AKT signaling. Despite the modest effect of survivin knockdown on tumor growth, reduction of the translationally regulated survivin profoundly inhibited motility and metastasis of CRC. These findings reveal a critical mechanism underlying the translational regulation of CRC metastatic progression, and suggest that targeting cap-dependent translation may provide a promising treatment strategy for advanced CRC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- 4E-BP1:
-
4E-binding protein 1
- CRC:
-
colorectal cancer
- DMSO:
-
dimethyl sulfoxide
- eIF4E:
-
eukaryotic translation initiation factor 4E
- ERK:
-
extracellular signal-regulated kinase
- MEK:
-
mitogen-activated extracellular signal-regulated kinase
- mTOR:
-
mammalian target of rapamycin
- mTORC1:
-
mammalian target of rapamycin complex 1
- PI3K:
-
phosphatidylinositol 3-kinase
- PIK3CA:
-
p110α catalytic subunit of PI3K
- UTR:
-
untranslated region.
References
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.
Chu E . An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin Colorectal Cancer 2012; 11: 1–13.
Sebolt-Leopold JS, Herrera R . Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004; 4: 937–947.
Cancer Genome Atlas Research Network, Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330–337.
Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, DeLong L et al. Colorectal cancer: mutations in a signalling pathway. Nature 2005; 436: 792.
Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009; 69: 4286–4293.
Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ . Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer 2009; 125: 2332–2341.
She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010; 18: 39–51.
Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB et al. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res 2010; 70: 6804–6814.
Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483: 100–103.
Sonenberg N, Hinnebusch AG . Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009; 136: 731–745.
Mamane Y, Petroulakis E, Martineau Y, Sato TA, Larsson O, Rajasekhar VK et al. Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS One 2007; 2: e242.
Livingstone M, Atas E, Meller A, Sonenberg N . Mechanisms governing the control of mRNA translation. Phys Biol 2010; 7: 021001.
Silvera D, Formenti SC, Schneider RJ . Translational control in cancer. Nat Rev Cancer 2010; 10: 254–266.
Rosenwald IB, Chen JJ, Wang S, Savas L, London IM, Pullman J . Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene 1999; 18: 2507–2517.
Berkel HJ, Turbat-Herrera EA, Shi R, de Benedetti A . Expression of the translation initiation factor eIF4E in the polyp-cancer sequence in the colon. Cancer Epidemiol Biomarkers Prev 2001; 10: 663–666.
Martin ME, Perez MI, Redondo C, Alvarez MI, Salinas M, Fando JL . 4E binding protein 1 expression is inversely correlated to the progression of gastrointestinal cancers. Int J Biochem Cell Biol 2000; 32: 633–642.
Armengol G, Rojo F, Castellvi J, Iglesias C, Cuatrecasas M, Pons B et al. 4E-binding protein 1: a key molecular ‘funnel factor’ in human cancer with clinical implications. Cancer Res 2007; 67: 7551–7555.
Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 2011; 29: 4688–4695.
Hanrahan AJ, Schultz N, Westfal ML, Sakr RA, Giri DD, Scarperi S et al. Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov 2012; 2: 56–67.
Altieri DC . Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8: 61–70.
Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T, Altieri DC . IAP regulation of metastasis. Cancer Cell 2010; 17: 53–64.
McKenzie JA, Liu T, Goodson AG, Grossman D . Survivin enhances motility of melanoma cells by supporting Akt activation and alpha 5 integrin upregulation. Cancer Res 2010; 70: 7927–7937.
Zhang M, Coen JJ, Suzuki Y, Siedow MR, Niemierko A, Khor LY et al. Survivin is a potential mediator of prostate cancer metastasis. Int J Radiat Oncol Biol Phys 2010; 78: 1095–1103.
Chu XY, Chen LB, Wang JH, Su QS, Yang JR, Lin Y et al. Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer. J Surg Oncol 2012; 105: 520–528.
Zoncu R, Efeyan A, Sabatini DM . mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21–35.
Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC . Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 2002; 10: 151–162.
Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP . Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005; 121: 179–193.
Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009; 7: e38.
Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009; 284: 8023–8032.
Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010; 70: 288–298.
Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110: 163–175.
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM . Phosphorylation and regulation of Akt/PKB by the rictor–mTOR complex. Science 2005; 307: 1098–1101.
Dilling MB, Germain GS, Dudkin L, Jayaraman AL, Zhang X, Harwood FC et al. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem 2002; 277: 13907–13917.
Ilic N, Utermark T, Widlund HR, Roberts TM . PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci USA 2011; 108: E699–E708.
Zindy P, Berge Y, Allal B, Filleron T, Pierredon S, Cammas A et al. Formation of the eIF4F translation–initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors. Cancer Res 2011; 71: 4068–4073.
Nguyen DX, Massague J . Genetic determinants of cancer metastasis. Nat Rev Genet 2007; 8: 341–352.
Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J et al. Global quantification of mammalian gene expression control. Nature 2011; 473: 337–342.
Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT et al. Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer 2011; 10: 188–193.
Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N . mTOR, translation initiation and cancer. Oncogene 2006; 25: 6416–6422.
Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M et al. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res 2011; 71: 3246–3256.
Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012; 485: 55–61.
Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65: 7052–7058.
O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500–1508.
Mazzoletti M, Bortolin F, Brunelli L, Pastorelli R, Di Giandomenico S, Erba E et al. Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates. Cancer Res 2011; 71: 4573–4584.
Thomas HE, Mercer CA, Carnevalli LS, Park J, Andersen JB, Conner EA et al. mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci Transl Med 2012; 4: 139ra184.
Floc'h N, Kinkade CW, Kobayashi T, Aytes A, Lefebvre C, Mitrofanova A et al. Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. Cancer Res 2012; 72: 4483–4493.
Moroz E, Carlin S, Dyomina K, Burke S, Thaler HT, Blasberg R et al. Real-time imaging of HIF-1alpha stabilization and degradation. PLoS One 2009; 4: e5077.
Pause A, Belsham GJ, Gingras AC, Donze O, Lin TA, Lawrence JC et al. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature 1994; 371: 762–767.
Zaytseva YY, Rychahou PG, Gulhati P, Elliott VA, Mustain WC, O’Connor K et al. Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer. Cancer Res 2012; 72: 1504–1517.
She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR et al. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 2008; 3: e3065.
Acknowledgements
We thank Drs Rina Plattner and Kathleen O’Connor and Ms Donna Gilbreath for critical reading and editing of this manuscript, Dr Ronald Blasberg for providing the SFG-FLuc-IRES2-GFP construct. Dr Piotr Rychahou for the assistance in the animal experiments, and Ms Dana Napier for the histologic tissue processing. This work was supported by grants from NCI (R01CA175105 to Q-B She, P30CA147886 and Gastrointestinal Cancer SPORE P20CA150343 to BM Evers), ACS (IRG85-001-22 to Q-B She), NIH/NCATS UL1RR033173 (KL2RR0033171 to Q-B She), and the Markey Cancer Center Start-up fund (to Q-B She).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Ye, Q., Cai, W., Zheng, Y. et al. ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene 33, 1828–1839 (2014). https://doi.org/10.1038/onc.2013.122
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2013.122
Keywords
This article is cited by
-
ZNF582 overexpression restrains the progression of clear cell renal cell carcinoma by enhancing the binding of TJP2 and ERK2 and inhibiting ERK2 phosphorylation
Cell Death & Disease (2023)
-
Solanum nigrum Linn.: Advances in anti-cancer activity and mechanism in digestive system tumors
Medical Oncology (2023)
-
Overexpression of microRNA-29b inhibits epithelial-mesenchymal transition and angiogenesis of colorectal cancer through the ETV4/ERK/EGFR axis
Cancer Cell International (2021)
-
ERK signalling: a master regulator of cell behaviour, life and fate
Nature Reviews Molecular Cell Biology (2020)
-
Spermine synthase and MYC cooperate to maintain colorectal cancer cell survival by repressing Bim expression
Nature Communications (2020)